XERSXeris Biopharma Holdings, Inc.

Nasdaq xerispharma.com


$ 2.15 $ -0.02 (-1.15 %)    

Monday, 08-Jul-2024 13:49:48 EDT
QQQ $ 497.00 $ 0.47 (0.09 %)
DIA $ 393.46 $ -0.24 (-0.06 %)
SPY $ 555.14 $ 0.23 (0.04 %)
TLT $ 92.76 $ 0.33 (0.35 %)
GLD $ 217.94 $ -2.99 (-1.35 %)
$ 2.11
$ 2.17
$ 2.14 x 600
$ 2.16 x 223
$ 2.13 - $ 2.26
$ 1.46 - $ 3.26
624,204
na
296.48M
$ 1.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-06-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-08-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-11-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 xeris-biopharma-names-john-shannon-to-succeed-paul-edick-as-new-ceo-and-board-director

The company announced a CEO succession plan effective August 1, 2024, under which Paul R. Edick will be retiring from his day-t...

 hc-wainwright--co-reiterates-buy-on-xeris-biopharma-holdings-maintains-6-price-target

HC Wainwright & Co. analyst Oren Livnat reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and maintains $6 pr...

 xeris-reports-topline-results-from-its-recently-completed-phase-2-open-label-study-of-xp-8121-for-treatment-of-adults-with-hypothyroidism

Participants who completed the study rated higher treatment satisfaction with XP-8121 compared to oral and a majority (72%) ind...

 piper-sandler-reiterates-overweight-on-xeris-biopharma-holdings-lowers-price-target-to-3

Piper Sandler analyst David Amsellem reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and lowers the pric...

 xeris-biopharma-holdings-q1-eps-014-misses-012-estimate-sales-4064m-miss-4181m-estimate

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estima...

 why-are-xeris-biopharma-shares-moving-monday

Xeris Biopharma shares are up Monday after the company announced an exclusive worldwide collaboration and license agreement wit...

 xeris-biopharma-enters-into-an-exclusive-worldwide-collaboration-and-license-agreement-with-beta-bionics-financial-terms-undisclosed

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives ...

 oppenheimer-initiates-coverage-on-xeris-biopharma-holdings-with-outperform-rating-announces-price-target-of-5

Oppenheimer analyst Leland Gershell initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform rating an...

 hc-wainwright--co-maintains-buy-on-xeris-biopharma-holdings-raises-price-target-to-6

HC Wainwright & Co. analyst Oren Livnat maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and raises the price...

 xeris-biopharma-holdings-q4-gaap-eps-010-inline-sales-4439m-beat-4355m-estimate

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate....

 earnings-scheduled-for-march-6-2024

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue o...

 why-wd-40-shares-are-trading-higher-by-over-17-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected ...